The kidneys of patients living with systemic lupus erythematosus (SLE) are often under assault, and not all those living with the disease will respond to standard treatment. A new report published in the journal Nature Immunology online May 20 shows how tissue samples from these patients can accurately predict those more likely than not to respond to therapy. SLE is a disease marked by the attack on joints, skin, and kidneys by the body's immune system..
Osteopontin (OPN) is a protein present in the bone and other tissues. Elevated levels of OPN have been observed in several autoimmune diseases including lupus. Investigators from a group called Systemic Lupus International Collaborating Clinics (SLICC) examined data from 344 people with lupus over the course of five years to determine whether raised OPN is a reliable biomarker for lupus. Specifically, they wanted to know if increased levels of OPN could predict damage; reflect current disease activity; or if increased OPN levels are associated with certain disease phenotypes (characteristics).
A 20-year study of women with lupus has found strong evidence that depression increases a person’s risk of developing lupus. That insight casts doubt on the generally accepted belief that depression is simply a by-product of having lupus. If depression is the chicken and lupus is the egg, the researchers found that the chicken could come first.
One-quarter of systemic lupus erythematosus patients in the U.S. taking hydroxychloroquine tablets daily are exceeding the recommended doses for this treatment, and up to one-third of those on alternate-day treatment are forgetting or mixing up their medication, a study reports.
The problem, researchers say, is that only 200 mg tablets exist – and many patients are prescribed a 300 mg dose. New dosage forms are needed to ensure proper treatment, researchers recommend.
Treatment with the investigational vaccine IFN-alpha Kinoid increased the number of systemic lupus erythematosus (SLE) patients achieving low disease activity, lessened their use of corticosteroids, and was well-tolerated, according to full results of a Phase 2b trial.
The findings, “IFN Kinoid in Systemic Lupus Erythematosus (SLE): Results from a Phase IIb, Randomized, Placebo-Controlled Study,” were presented at the 13th International Congress on Systemic Lupus Erythematosus (LUPUS 2019) by Frédéric Houssiau, MD, PhD, a professor at the Université Catholique de Louvain in Belgium, and the chairman of the trial.
Physical Exercise and Psychological Interventions Complement Usual Medical Care in Lupus.
Over the last two decades more research has been conducted which looks at non pharmacological therapies as a potential adjunct (add on) treatment to relieve lupus symptoms such a pain, fatigue, depression, quality of life and disease activity. Researchers in a new study conducted an updated literature review to bring together major findings and allow for some conclusions to be drawn.
A study of pregnant women with systemic lupus erythematosus has identified early changes in the RNA molecules present in the blood that could be used to determine the likelihood of them developing preeclampsia.
The study, which is published in the Journal of Experimental Medicine, may also help researchers develop treatments to prevent other pregnancy complications associated with lupus, including miscarriage and premature birth.
Childhood-onset systemic lupus erythematosus (cSLE) accounts for 10-20 percent of all people living with lupus. Understanding the living experience of adolescents and young adults (AYAs) with cSLE is an important first step in developing interventions to aid in self-management and adherence.
A new study surveyed AYAs from a Midwestern children’s hospital with cSLE between the ages of 12 and 24, and 44 primary caregivers, about living with lupus.
Patients with lupus, an inflammatory disease in which the body's immune system attacks its own tissues, are on average seven to nine times more likely to develop heart disease than the general population. Younger women with lupus are 50 times as likely to develop the disease as young women without the disease.
The endothelium -- the single layer of cells lining blood vessel walls -- is thought to protect against heart disease. It does so in part by producing nitric oxide.
Lupus can be a stubborn disease to treat. Although many struck by the autoimmune condition live relatively normal lives, some suffer from kidney failure, blood clots, and other complications that can be deadly. Now, scientists have found that a novel treatment that wipes out the immune system’s B cells cures mice of the condition. Though the work is preliminary, it has excited researchers because it uses a therapy already approved for people with blood cancer.
“This is a critical stepping stone,” says Jennifer Anolik, a rheumatologist who runs the lupus clinic at the University of Rochester Medical Center in New York who was not involved with the work.
Autoimmune diseases, such as systemic lupus erythematosus or rheumatoid arthritis, are difficult to diagnose, specially in early stages. Specifically, in the case of lupus, specific antibodies aimed at antigens located in the nucleus of cells appear, including the anti-Ro/SSA. These anti-Ro/SSA antibodies can be found in the blood before other autoantibodies related with lupus, and can even be detected without the existence of symptoms.
People with lupus and rheumatoid arthritis (RA) have a greater risk of developing cardiovascular diseases (CVD) and atherosclerosis. A new study conducted in Columbia has identified potential new therapeutic targets for reducing endothelial damage (defined as the destruction of the membrane that lines the inside of the heart and blood vessels).